Apimeds Pharmaceuticals US, Inc (APUS) Revenue History
Annual and quarterly revenue from 2021 to present
APUS Revenue Over Time (2021–2025)
APUS Revenue Growth History
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
APUS Revenue Analysis (2021–2025)
Current Revenue & Growth
As of June 28, 2026, Apimeds Pharmaceuticals US, Inc (APUS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
APUS's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including HALO (+39.1% YoY), ACRS (-52.9% YoY), and NUVB (+1205.5% YoY). Compare APUS vs HALO →
APUS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| APUSCurrent | $0 | - | - | - | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% | |
 ACRS | $8M | -52.9% | +3.8% | -975.9% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% |
APUS Historical Revenue Data (2021–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-5,706 | - | $-11,912,562 | - |
| 2024 | $0 | - | $0 | - | $-1,275,095 | - |
| 2023 | $0 | - | $0 | - | $-747,436 | - |
| 2022 | $0 | - | $0 | - | $-639,529 | - |
| 2021 | $0 | - | $0 | - | $-1,019,494 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
APUS — Frequently Asked Questions
Quick answers to the most common questions about buying APUS stock.
Is APUS's revenue growth accelerating or slowing?
APUS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is APUS's revenue history from 2021 to 2026?
Apimeds Pharmaceuticals US, Inc (APUS) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is APUS's long-term revenue growth rate (CAGR)?
Apimeds Pharmaceuticals US, Inc's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for APUS.
Why does APUS's quarterly revenue fluctuate?
APUS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Apimeds Pharmaceuticals US, Inc's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is APUS's revenue distributed by segment?
APUS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does APUS's revenue compare to industry peers?
Apimeds Pharmaceuticals US, Inc (APUS) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.